As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
13 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
13 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 598 598 |
56%
56%
|
|
| Gross Profit | 523 523 |
58%
58%
|
|
| EBITDA | 40 40 |
262%
262%
|
|
| EBIT (Operating Income) EBIT | 38 38 |
245%
245%
|
|
| Net Profit | 36 36 |
496%
496%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
| Head office | Bermuda |
| CEO | Sanj Patel |
| Employees | 315 |
| Founded | 2015 |
| Website | www.kiniksa.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


